Skip to main content
. 2015 Apr 3;6(14):12209–12223. doi: 10.18632/oncotarget.3528

Figure 1. Optimisation of FKBPL antibody for IHC.

Figure 1

(A) Optimisation of the FKBPL anti-body for IHC staining. Specificity was verified via Western blotting, and optimized for IHC using cell pellet arrays of parental (MCF-7 and MDA-B-231) and FKBPL overexpressing (3.1D2, 3.1D9; derived from MCF-7 and A3; derived from MDA-231) cell lines or following siRNA-mediated knockdown of FKBPL in MCF-7 cells. (B) Various expression levels of FKBPL protein in invasive breast carcinoma. Images (x10) represent tumour sections with absent (0), low (1+), moderate (2+) and high (3+) immunohistochemical staining intensity for FKBPL.